Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population

Background: Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently. Methods: Between February 2019 to December 2021, 95 female hormone receptor-positive (HR+)/h...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yusi, Chen, Wenlin, Chen, Shuanglong, Yang, Qingmo, Ouyang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Screening, Diagnosis, and Treatment of Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623362/
https://www.ncbi.nlm.nih.gov/pubmed/36310472
http://dx.doi.org/10.1177/15330338221132926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623362/
https://www.ncbi.nlm.nih.gov/pubmed/36310472
http://dx.doi.org/10.1177/15330338221132926

Ejemplares similares